I emailed Matt and received the below answers.
I asked if 1801 could bypass phase 1 trials and also how would this be funded.
Matt said that 1801 can go straight into clinical studies as we've announced because we already have safety data on topical delivery of CBD. How and when we do that is under consideration, both whether we fund or work with someone else.
Would the potential products be used in vet medicine.
Animals would also be a great target as they suffer from dermatitis and infections.
4215
Psoriasis results, page-47
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $425.2M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 26.8¢ | $2.645M | 9.461M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 1008444 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 24999 | 1 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.0¢ |
Change
-0.010 ( 3.91 %) |
||||
| Open | High | Low | Volume | ||
| 28.8¢ | 29.0¢ | 26.5¢ | 5418297 | ||
| Last updated 15.59pm 14/05/2024 ? | |||||
| BOT (ASX) Chart |